Findings

What do systematic reviews say?

219 questions · 228 findings · 18 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 36 · 15.8%GRADE not reported 9 · 3.9%Very low 30 · 13.2%Low 71 · 31.1%Moderate 60 · 26.3%High 22 · 9.6%

Parasympathomimetic drugs (choline esters, cholinesterase inhibitors) vs No treatment

Outcome not reported · Patients with radiation-induced salivary gland dysfunction

The review found no eligible studies for this question.

1 finding from 1 review

Parasympathomimetic drugs for the treatment of salivary gland dysfunction due to radiotherapy 2015 · Cochrane All outcomes
no estimate extracted
0 studies
No studies found

Intervention not reported

Cholinesterase inhibitor vs placebo · critically ill adult with confirmed or at high risk of delirium

1 finding from 1 review

Pharmacological interventions for the treatment of delirium in critically ill adults 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 104 participants
Moderate

Intervention not reported

Cholinesterase Inhibitor vs placebo · critically ill adult with confirmed or at high risk of delirium

1 finding from 1 review

Pharmacological interventions for the treatment of delirium in critically ill adults 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 104 participants
Moderate

Intervention not reported

Cholinesterase inhibitor vs placebo · critically ill adults with confirmed or at high risk of delirium

1 finding from 1 review

Pharmacological interventions for the treatment of delirium in critically ill adults 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 104 participants
Moderate

Continuous positive airway pressure (CPAP) vs phosphodiesterase type 5 inhibitors

Erectile dysfunction · erectile dysfunction in men with obstructive sleep apnoea

1 finding from 1 review

Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 152 participants
Low

Continuous positive airway pressure (CPAP) vs phosphodiesterase type 5 inhibitors

Serious adverse events · erectile dysfunction in men with obstructive sleep apnoea

1 finding from 1 review

Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Very low

Continuous positive airway pressure (CPAP) vs phosphodiesterase type 5 inhibitors

Sex‐related quality of life (QoL) · erectile dysfunction in men with obstructive sleep apnoea

1 finding from 1 review

Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 122 participants
Very low

Continuous positive airway pressure (CPAP) vs phosphodiesterase type 5 inhibitors

Health‐related quality of life · erectile dysfunction in men with obstructive sleep apnoea

The review found no eligible studies for this question.

1 finding from 1 review

Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Continuous positive airway pressure (CPAP) vs phosphodiesterase type 5 inhibitors

Minor adverse events · erectile dysfunction in men with obstructive sleep apnoea

It is very uncertain whether continuous positive airway pressure (CPAP) changes minor adverse events compared with phosphodiesterase type 5 inhibitors (very low certainty).

1 finding from 1 review

Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea 2021 · Cochrane Headline outcomes only
RR 1.33 [0.34, 5.21]
1 study · 40 participants
Very low

Galantamine plus risperidone vs placebo plus risperidone

Overall autism features Not assessed · children and adolescents with a diagnosis of autism

The review found no eligible studies for this question.

1 finding from 1 review

Acetylcholinesterase inhibitors for autistic spectrum disorders 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Donepezil vs placebo

Repetitive and restricted behaviour (Sensory Motor subscale of RLRS; raw score means; lower = better) · children and adolescents with a diagnosis of autism

1 finding from 1 review

Acetylcholinesterase inhibitors for autistic spectrum disorders 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Very low

Donepezil vs placebo

Side effects or other adverse events · children and adolescents with a diagnosis of autism

1 finding from 1 review

Acetylcholinesterase inhibitors for autistic spectrum disorders 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Very low

Donepezil vs placebo

Irritability · children and adolescents with a diagnosis of autism

1 finding from 1 review

Acetylcholinesterase inhibitors for autistic spectrum disorders 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Very low

Donepezil vs placebo

Hyperactivity (Child Behaviour Checklist Attention problems Subscale; lower = better) · children and adolescents with a diagnosis of autism

1 finding from 1 review

Acetylcholinesterase inhibitors for autistic spectrum disorders 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Very low

Donepezil vs placebo

General health and function (Severity of Illness subscale of Clinical Global Impression Scale; lower = better) · children and adolescents with a diagnosis of autism

1 finding from 1 review

Acetylcholinesterase inhibitors for autistic spectrum disorders 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Very low

Galantamine plus risperidone vs placebo plus risperidone

Social communication (Lethargy/Social withdrawal subscale of the ABC‐C; 0 to 64; lower = better) · children and adolescents with a diagnosis of autism

1 finding from 1 review

Acetylcholinesterase inhibitors for autistic spectrum disorders 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Very low

Galantamine plus risperidone vs placebo plus risperidone

Stereotypical behaviours · children and adolescents with a diagnosis of autism

1 finding from 1 review

Acetylcholinesterase inhibitors for autistic spectrum disorders 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Very low

Galantamine plus risperidone vs placebo plus risperidone

Side effects or other adverse events · children and adolescents with a diagnosis of autism

Galantamine plus risperidone may leads to higher adverse events (Side Effects Checklist) compared with placebo plus risperidone (low certainty).

1 finding from 1 review

Acetylcholinesterase inhibitors for autistic spectrum disorders 2023 · Cochrane Headline outcomes only
OR 5.57 [1.42, 21.86]
1 study · 40 participants
Low

Galantamine plus risperidone vs placebo plus risperidone

Irritability · children and adolescents with a diagnosis of autism

1 finding from 1 review

Acetylcholinesterase inhibitors for autistic spectrum disorders 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Low

Galantamine plus risperidone vs placebo plus risperidone

Hyperactivity · children and adolescents with a diagnosis of autism

1 finding from 1 review

Acetylcholinesterase inhibitors for autistic spectrum disorders 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Low